Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Commodities

Legal Battle Sparks Sell-Off in Almonty Shares

Dieter Jaworski by Dieter Jaworski
October 22, 2025
in Commodities, Mergers & Acquisitions, Penny Stocks
0
Almonty Industries Stock
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Almonty Industries Inc. finds itself navigating turbulent market conditions as its stock faces significant downward pressure following the initiation of legal proceedings against Pure Tungsten Inc. The tungsten specialist has filed a lawsuit with the Ontario Superior Court of Justice, seeking an injunction against what it describes as “materially false and misleading statements” disseminated by the other company.

Share Price Plunge Reflects Investor Concerns

Market reaction to the legal dispute has been decidedly negative, with Almonty’s NASDAQ-listed shares declining approximately 12% to $7.92. Trading activity tells a concerning story, with volume running 36% below average levels. This combination of price deterioration and subdued participation indicates growing bearish sentiment among market participants.

Recent trading sessions have revealed substantial volatility in the equity:
– October 21: Closing price of $8.38, representing a decline of 6.89%
– October 17: Trading range between $7.37 and $8.26
– October 16: Retreat from $9.68 to $8.51

Technical Indicators Flash Warning Signals

Multiple technical analysis tools are currently suggesting caution for investors:

• MACD indicator showing death cross formation on 15-minute charts
• Bollinger Bands contracting, suggesting potential volatility expansion
• Trading volume remaining substantially below normal averages
• Critical support zone between $7.90 and $8.00 undergoing testing

Should investors sell immediately? Or is it worth buying Almonty Industries?

Legal Action Targets Alleged Misinformation

The litigation specifically addresses what Almonty claims are inaccurate representations concerning its flagship Sangdong mine and false assertions regarding Tiger Kim’s historical involvement with the company. The company has issued categorical denials, stating unequivocally that Kim never held any executive position. His limited engagement as an independent contractor concluded on December 31, 2015.

Chief Executive Lewis Black emphasized the seriousness of the situation, stating that Pure Tungsten’s “disinformation campaign against Almonty directly threatens market integrity and our shareholders’ interests.” The company is pursuing all available legal avenues to correct statements it believes to be factually incorrect.

The legal filing requests judicial intervention to:
– Prohibit Pure Tungsten from circulating further inaccurate statements
– Mandate corrective disclosures regarding executive claims
– Require retraction of misleading comparisons between mineral deposits

Strategic Positioning Remains Intact

Despite the legal controversy, Almonty’s fundamental strategic advantages appear unchanged. The Sangdong mine in South Korea is projected to supply more than 80% of global non-Chinese tungsten production once operating at full capacity. Against the backdrop of U.S. procurement restrictions and Chinese export limitations, the company maintains its position as a strategic supplier of critical materials.

The current legal confrontation serves as a crucial test of Almonty’s commitment to market transparency within an increasingly complex geopolitical landscape for essential minerals. How effectively the company navigates these challenges will likely determine its ability to restore investor confidence moving forward.

Ad

Almonty Industries Stock: Buy or Sell?! New Almonty Industries Analysis from February 7 delivers the answer:

The latest Almonty Industries figures speak for themselves: Urgent action needed for Almonty Industries investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Almonty Industries: Buy or sell? Read more here...

Tags: Almonty Industries
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock
Gaming & Metaverse

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
OneSpan Stock
Cyber Security

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026
Next Post
Bitcoin Stock

Bitcoin Approaches Critical Juncture Amid Market Volatility and Regulatory Shifts

Deutsche Bank Stock

Deutsche Bank Shares Face Critical Test Amid Diverging Views

Standard Lithium Stock

Standard Lithium Secures Major Funding Injection Amid Market Optimism

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com